Eric Bernicker

6.3k total citations
77 papers, 1.2k citations indexed

About

Eric Bernicker is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Eric Bernicker has authored 77 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 38 papers in Oncology and 15 papers in Cancer Research. Recurrent topics in Eric Bernicker's work include Lung Cancer Treatments and Mutations (33 papers), Cancer Genomics and Diagnostics (15 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Eric Bernicker is often cited by papers focused on Lung Cancer Treatments and Mutations (33 papers), Cancer Genomics and Diagnostics (15 papers) and Cancer Immunotherapy and Biomarkers (15 papers). Eric Bernicker collaborates with scholars based in United States, China and France. Eric Bernicker's co-authors include Barry Trachtenberg, Kartik Anand, Joe Ensor, Bin S. Teh, E. Brian Butler, Andrew Farach, Philip T. Cagle, Stephen B. Greenberg, David L. Schaffner and Amy C Schefler and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Eric Bernicker

76 papers receiving 1.2k citations

Peers

Countries citing papers authored by Eric Bernicker

Since Specialization

Citations

This map shows the geographic impact of Eric Bernicker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Bernicker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Bernicker more than expected).

Fields of papers citing papers by Eric Bernicker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Bernicker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Bernicker. The network helps show where Eric Bernicker may publish in the future.

Co-authorship network of co-authors of Eric Bernicker

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Bernicker. A scholar is included among the top collaborators of Eric Bernicker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Bernicker. Eric Bernicker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer 2024 ·Cells ·(unknown), Yitian Xu, Randall J. Olsen, Saro Kasparian, (unknown), (unknown), Jun Zhang, Chuan He, Shu‐Hsia Chen, Eric Bernicker, Zejuan Li	4
2	Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease 2023 ·Frontiers in Oncology ·Emily Allen, (unknown), (unknown), Eric Bernicker	1
3	Lung Cancer Screening Eligibility and Referral Practices in Texas Organizations Serving People with Substance Use Disorders 2023 ·Cancers ·(unknown), Tzu-An Chen, Isabel Martinez Leal, (unknown), Bryce Kyburz, Teresa Williams, (unknown), Randa El‐Zein, Eric Bernicker, Lisa M. Lowenstein, Lorraine R. Reitzel	2
4	A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM). 2023 ·Journal of Clinical Oncology* ·Diwakar Davar, Alexandra P. Ikeguchi, Elizabeth I. Buchbinder, Alexander N. Shoushtari, (unknown), Eric Bernicker, Sarah A. Weiss, Gregory A. Daniels, Timothy J. Panella, (unknown), Howard Goodall, Ryan J. Sullivan	4
5	Environmental Oncology 2023 ·Eric Bernicker	2
6	Treatment at Twilight: An Analysis of Therapy Patterns and Outcomes in Adults 80 Years and Older With Advanced or Metastatic NSCLC 2023 ·JTO Clinical and Research Reports ·Ethan Burns, (unknown), (unknown), (unknown), Jun Zhang, Eric Bernicker	2
7	Lung adenocarcinoma in a patient with Lynch syndrome: a case report and literature review 2023 ·Frontiers in Oncology ·Alan W. Hodges, (unknown), Tiffany G. Sheu, Eric Bernicker	1
8	Comparison of Tumor Size and Gene Expression at Presentation in Uveal Melanoma Patients before and during the COVID-19 Pandemic 2022 ·Ocular Oncology and Pathology ·Naomi Hasegawa, (unknown), Eric Bernicker, Bin S. Teh, Amy C Schefler	1
9	DMSA-SPECT: A Novel Approach to Nephron Sparing SBRT for Renal Cell Carcinoma 2021 ·Advances in Radiation Oncology ·(unknown), Stephen Chiang, Andrew Farach, Waqar Haque, Raj Satkunasivam, Eric Bernicker, Ramiro Pino, E. Brian Butler, Bin S. Teh	4
10	1024P Baseline biomarkers associated with clinical benefit in patients with solid tumors refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumab 2021 ·Annals of Oncology ·Edwin R. Parra, (unknown), (unknown), (unknown), Cara Haymaker, (unknown), Eric Bernicker, Diwakar Davar, A.P. Chaudhry, Alexander J. Stevenson, (unknown), (unknown), Michael Chisamore, Shubham Pant	4
11	Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database 2020 ·Journal of Contemporary Brachytherapy ·J.A. Messer, (unknown), Waqar Haque, Gary D. Lewis, Amy C Schefler, Andrew Wong, Eric Bernicker, Patricia Chévez‐Barrios, Enzhuo Quan, Andrew Farach, E. Brian Butler, Sandra S. Hatch, Bin S. Teh	10
12	Osimertinib-Induced Cardiotoxicity 2019 ·JACC CardioOncology ·Kartik Anand, Joe Ensor, Barry Trachtenberg, Eric Bernicker	141
13	Update on emerging biomarkers in lung cancer 2019 ·Journal of Thoracic Disease ·Eric Bernicker, Timothy Craig Allen, (unknown)	20
14	Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma 2019 ·Graefe s Archive for Clinical and Experimental Ophthalmology ·Amy C Schefler, (unknown), Eric Bernicker, Zélia M. Corrêa	25
15	Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer 2019 ·JACC CardioOncology ·Kalyan R. Chitturi, Jiaqiong Xu, (unknown), Arvind Bhimaraj, Ashrith Guha, Imad Hussain, Mahwash Kassi, Eric Bernicker, Barry Trachtenberg	70
16	Community-based Disparities in the Treatment and Outcomes of Early-stage Non-small-cell Carcinoma 2019 ·Cureus ·(unknown), Bin S. Teh, Eric Bernicker, E. Brian Butler, Andrew Farach	3
17	Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer 2018 ·Clinical Cancer Research ·Sarah Croessmann, Luigi Formisano, Lisa N. Kinch, Paula I. González-Ericsson, Dhivya R. Sudhan, Rebecca J. Nagy, Aju Mathew, Eric Bernicker, Massimo Cristofanilli, Jie He, Richard E. Cutler, Alshad S. Lalani, Vincent A. Miller, Richard B. Lanman, Nick V. Grishin, Carlos L. Arteaga	78
18	Disparities in the Treatment and Outcome of Stage I Non–Small-Cell Lung Cancer in the 21st Century 2018 ·Clinical Lung Cancer ·(unknown), Gary D. Lewis, Eric Bernicker, E. Brian Butler, Bin S. Teh, Andrew Farach	25
19	Chemotherapy in non-small cell lung cancer: opportunities for advancement 2016 ·Chinese Journal of Cancer ·Mani Akhtari, Eric Bernicker, Bin S. Teh	5
20	Unanticipated Diagnoses Found at Autopsy in an Urban Public Teaching Hospital 1996 ·The American Journal of the Medical Sciences ·Eric Bernicker, Robert L. Atmar, David L. Schaffner, Stephen B. Greenberg	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact